Solasia Signs a License Agreement with Isofol to Develop and Commercialize Arfolitixorin for mCRC in Japan

 Solasia Signs a License Agreement with Isofol to Develop and Commercialize Arfolitixorin for mCRC in Japan

Solasia Signs a License Agreement with Isofol to Develop and Commercialize Arfolitixorin for mCRC in Japan

Shots:

  • Isofol to receive $100M as up front, development, regulatory and commercial milestones, and clinical development cost and is eligible to receive royalties on sales of the therapy and retain its right to the therapy in ROW
  • Solasia will lead clinical development activities in Japan and will be responsible for registrational filing and approval in the licensed territory. The collaboration will initially focus on the development and commercialization of arfolitixorin as 1L treatment for mCRC patients and may extend it to other indications
  • Arfolitixorin is currently being evaluated in the ongoing global P-III AGENT study, conducted in the US, Canada, EU, Australia, and Japan. Isofol and Solasia plan to expand the study with additional sites in Japan while Isofol will remain as global sponsor of the study

Click here ­to­ read full press release/ article | Ref: Isofol | Image: CNN

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post